Scarica l'app Stockscreener
150.85
5.20%
-8.27
Pre-mercato:
148.54
-2.31
-1.53%
Precedente Chiudi:
$159.12
Aprire:
$157.54
Volume 24 ore:
1.40M
Relative Volume:
1.38
Capitalizzazione di mercato:
$7.27B
Reddito:
$4.02B
Utile/perdita netta:
$-142.16M
Rapporto P/E:
-51.03
EPS:
-2.9563
Flusso di cassa netto:
$518.49M
1 W Prestazione:
-15.07%
1M Prestazione:
-16.45%
6M Prestazione:
-10.11%
1 anno Prestazione:
+8.61%
Intervallo 1D:
$149.98
$160.26
Intervallo di 1 settimana:
$149.98
$178.41
Portata 52W:
$132.58
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
150.85 | 7.66B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-17 | Aggiornamento | Argus | Hold → Buy |
| 2025-11-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform - simplywall.st
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MSN
Charles River (CRL) reliance on international sales: What investors need to know - MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Director Nancy Andrews gifts Charles River (CRL) shares to trust - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance - AD HOC NEWS
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - BioSpace
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories stock (US1591881009): Shareholders approve 2026 incentive plan - AD HOC NEWS
Charles River (CRL) Partners with Medipost for Cell Therapy Adva - GuruFocus
Charles River Laboratories (CRL) Announces Approval of 2026 Long-Term Incentive Plan - GuruFocus
Director Steven Barg receives 1,438-share equity award at Charles River (NYSE: CRL) - Stock Titan
Charles River Labs (CRL) director receives 1,438-share equity award grant - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock grant - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut - AD HOC NEWS
Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Charles River Laboratories International Inc (CRL) Stock Down 5. - GuruFocus
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN
Charles River Labs Shareholders Approve New Incentive Plan - TipRanks
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor - Stock Titan
Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant - Stock Titan
Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants - Stock Titan
Director at Charles River (NYSE: CRL) gets 1,438-share equity grant - Stock Titan
Charles River (NYSE: CRL) director receives stock grants instead of fees - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock award - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,973-share equity award - Stock Titan
Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River - Stock Titan
Director James Foster gets 1,860 Charles River (NYSE: CRL) shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Charles River (CRL) Enhances Digital Pathology Platform for Fast - GuruFocus
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow - 01net
Charles River (CRL) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Charles River expands AI-enabled digital pathology platform By Investing.com - Investing.com Canada
Charles River Laboratories stock (US1591881009): Core business and market position - AD HOC NEWS
Charles River Laboratories stock: Is CRL underperforming the healthcare sector? - MSN
Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound? - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum - simplywall.st
Charles River Laboratories International Q1 Earnings Call Highlights - Barchart.com
MSN Money - MSN
Charles River Laboratories stock (US1591881009): Shares dip after recent run-up as analysts eye upsi - AD HOC NEWS
Charles River Laboratories Q1 2026 earnings preview - MSN
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results - Benzinga
Charles River Laboratories International, Inc. Seeks M&A Opportunities - marketscreener.com
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call Transcript - Insider Monkey
Mizuho raises Charles River Labs stock price target on steady results - Investing.com Canada
Charles River: Q1 Earnings Snapshot - theheraldreview.com
Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance - Moomoo
Johnson Opportunity Fund's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):